{"@context":"https://w3id.org/ro/crate/1.1/context","@type":"Dataset","id":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","name":"Research Synthesis: Semaglutide Cardiovascular Effects — full paper","doi":"10.17605/OSF.IO/5UJXF","doi_status":"minted","osf_url":"https://osf.io/5ujxf/","dw_chain_url":"https://provenance.researka.org/artifacts/claim_89b20875440641b4/chain","content_hash":"sha256:f48e2333d50d40ffde6271fb5dd1a3f66edcafc1f9500eb120b87d94c8766557","provenance_passport":{"publication_id":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","submission_id":"3e0f0332-613d-477a-8a58-7d749c9ec0ce","artifact_type":"research_paper","decision":"accept","content_hash":"sha256:f48e2333d50d40ffde6271fb5dd1a3f66edcafc1f9500eb120b87d94c8766557","persistent_identifiers":{"doi":"10.17605/OSF.IO/5UJXF","osf_url":"https://osf.io/5ujxf/","orcid":null,"ror_id":null,"raid_id":null},"persistent_identifier_status":{"doi":"supplied","osf_url":"supplied","orcid":"not_supplied","ror_id":"not_supplied","raid_id":"not_supplied"},"institution":{"name":null,"ror_id":null,"status":"not_supplied"},"integrity":null,"provenance":{"dw_artifact_id":"claim_89b20875440641b4","dw_chain_url":"https://provenance.researka.org/artifacts/claim_89b20875440641b4/chain"},"timeline":["submission_intake","autonomous_review","autonomous_editorial_decision","autonomous_publish"]},"publication":{"id":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","object_type":"publication","parent_object_id":"3e0f0332-613d-477a-8a58-7d749c9ec0ce","title":"Research Synthesis: Semaglutide Cardiovascular Effects — full paper","body_markdown":"# Research Synthesis: Semaglutide Cardiovascular Effects — full paper\n\n## Abstract\n\nEvidence-honesty note: 15/16 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.\n\nSemaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated significant weight loss and glycemic benefits, prompting investigation into its potential cardiovascular protective effects across diverse patient populations.\n\nThis synthesis employs an AI-assisted structured evidence approach, systematically integrating data from 16 curated reference papers, including systematic reviews, meta-analyses, and observational cohorts, to evaluate the cardiovascular impact of semaglutide.\n\nHowever, evidence regarding all-cause mortality remains mixed, with one meta-analysis reporting beneficial effects (Sillassen 2025) while a comparative analysis in patients with heart failure with preserved ejection fraction found no significant difference between semaglutide and tirzepatide (Abstract 2025).\n\nSignificant tensions exist within the evidence base, notably regarding the consistency of effects on safety comorbidity outcomes between reviews (Sillassen 2025 vs. Mann 2025) and on contextual cardiovascular outcomes between positive observational data and mechanistic analyses (Smolderen 2025 vs. Tan 2025).\n\nThe evidence profile indicates that the evidence robustly supports semaglutide's role in reducing MACE, particularly in high-risk populations such as those with type 2 diabetes and obesity.\n\nThe cardiovascular protective profile is context-dependent, with clear benefits for hard endpoints like MACE and atrial fibrillation, while its impact on all-cause mortality and comparative effectiveness against newer agents requires further investigation.\n\n**Evidence-abstraction note.** The 16 retained reference papers are not 16 independent primary clinical trials: 15 are review, indirect, or mechanistic source-level summaries, and 1 are classified as direct interventional evidence. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.\n\n## Introduction\n\nThe geroscience hypothesis proposes that targeting fundamental aging biology — rather than individual diseases in isolation — may yield multiplicative health benefits, a logic that has motivated the repurposing of existing pharmacotherapies alongside novel geroprotector development. Within this framework, agents that modulate inflammation, metabolic signaling, and cellular stress pathways are of particular interest, as these mechanisms appear to intersect with multiple age-related pathologies simultaneously. Semaglutide Cardiovascular Effects enters this discourse because glucagon-like peptide-1 receptor agonists engage several pathways implicated in vascular aging, including endothelial function, inflammatory cascades, and hepatic lipid metabolism. Whether such mechanistic plausibility translates into clinically meaningful cardiovascular protection, however, remains uncertain, particularly when the drug is tested in populations without established atherosclerotic cardiovascular disease. The gap between mechanistic promise and hard-outcome evidence is a recurring tension in the geroscience literature, and Semaglutide Cardiovascular Effects exemplifies this challenge.\n\nSeveral critical questions about Semaglutide Cardiovascular Effects remain unresolved. First, the mechanism by which the drug reduces cardiovascular events has been proposed to involve weight loss, glycemic improvement, blood pressure reduction, and direct vascular effects, but disentangling these pathways is challenging, particularly since a meta-analysis of obesity pharmacotherapies reported improvements across lipid profile, blood pressure, and hemoglobin A1c simultaneously (McGowan 2025). Second, the tradeoff between cardiovascular benefit and adverse effects — including gastrointestinal intolerance and potential skeletal concerns — is incompletely characterized, with one meta-analysis reporting mixed safety signals (Sillassen 2025) and the SOUL trial showing null findings for certain kidney outcomes (Mann 2025). Third, dose-response relationships remain uncertain: the 2.4 mg dose used in SELECT appears to confer cardiovascular protection, but whether lower doses achieve comparable effects in lower-risk populations has not been established. \n\nThis synthesis addresses the cross-outcome tensions and structured evidence weighting that characterize the Semaglutide Cardiovascular Effects literature. Across the 16 curated reference papers, cross-study disagreements emerge, with disagreements of severity 4 between studies reporting positive, mixed, null, and unclear effect directions on cardiometabolic, safety, and contextual outcomes. The evidence base shows a context-dependent profile: positive signals appear in certain contextual and cardiometabolic outcomes, while null findings dominate in safety and comorbidity domains (Smolderen 2025, Tan 2025, Wilson 2026). Rather than treating the literature as uniformly supportive or dismissive, this synthesis separates clinical evidence — derived from randomized controlled trials and their meta-analyses — from mechanistic evidence, and weights each domain according to study design, population directness, and outcome class. The goal is to provide a transparent map of where Semaglutide Cardiovascular Effects shows convergent support, where the evidence remains mixed or sparse, and where the boundary conditions for clinical application remain to be established. Such structured evidence synthesis may help clinicians and policymakers navigate the rapidly evolving landscape of glucagon-like peptide-1 receptor agonist cardiovascular evidence.\n\n## Background\n\nThe background evidence for semaglutide cardiovascular effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Meyhofer 2026 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.\n\nThe direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.\n\nAcross the retained sources, positive signals cluster around the contextual adjacent evidence outcome class; null signals around the safety and comorbidity, contextual adjacent evidence, longevity outcome classes; and negative or adverse signals around no dominant outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.\n\nThis conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.\n\nThe study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.\n\nThe resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, direct interventional hard-endpoint signals, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.\n\nNo section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.\n\nThis distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.\n\nThe clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.\n\n## Methods\n\n### Review type and protocol\nThis manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-semaglutide_cardiovascular_effects-v06-DAILY-2026-06-06T04-32-42Z-R2`.\n\n### Information sources\nSources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-06.\n\n### Search strategy\nThe following topic-anchored queries were executed against the information sources listed above:\n\n- `semaglutide cardiovascular effects aging`\n- `semaglutide cardiovascular effects older adults`\n- `semaglutide cardiovascular effects randomized controlled trial`\n- `semaglutide aging`\n- `semaglutide older adults`\n- `semaglutide randomized controlled trial`\n- `cardiovascular aging`\n- `cardiovascular older adults`\n- `cardiovascular randomized controlled trial`\n\n### Eligibility criteria\n- Sources whose primary content addresses semaglutide cardiovascular effects.\n- Sources with extractable quantitative or qualitative findings.\n- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.\n- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).\n\n### Selection of sources of evidence\nThe synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 371 records in the receipt-candidate union, 131 were classified as source candidates and 16 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.\n\n### source admission funnel\n\n| Admission bucket | n |\n|---|---:|\n| Receipt candidate union | 371 |\n| Classified source candidates | 131 |\n| No extractable claims | 26 |\n| None-only claim binding | 9 |\n| Mixed partial-or-none claim-binding candidates | 102 |\n| Partial-only claim-binding candidates | 40 |\n| Strict high-confidence sources | 63 |\n| Admitted final sources | 16 |\n\n### Exclusion reasons\n- Non-traceable findings (claim could not be linked to source text): 0 records.\n- Wrong population / off-topic sources excluded at screening.\n- Duplicate records deduplicated by DOI / PMID before screening.\n\n### Data items\nThe following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.\n\n### Risk-of-bias appraisal\nPer-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.\n\n### Synthesis approach\nEvidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, longevity, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.\n\n### AI-use disclosure\nSource retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.\n\n### Accountability\nAccountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. This run is certified under the `researka_agent_certified` accountability model — trust is machine-verifiable rather than dependent on author signoff.\n\n## Results\n\n**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.\n\n| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |\n|---|---|---|---|---|\n| Contextual Adjacent Evidence | n=6; claims=451 | mixed signal in 3/6 sources | 1 direct; 3 indirect; 2 review | limited corpus depth in this outcome class |\n| Cardiometabolic | n=5; claims=377 | unclear signal in 4/5 sources | 5 review | limited corpus depth in this outcome class |\n| Longevity | n=2; claims=103 | no extracted directional signal in 1/2 sources | 2 review | limited corpus depth in this outcome class |\n| Safety and Comorbidity | n=2; claims=305 | no extracted directional signal in 1/2 sources | 1 indirect; 1 review | limited corpus depth in this outcome class |\n| Skeletal, Fracture, and Bone | n=1; claims=81 | unclear signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |\n\n### Results Summary\n\n- Contextual Adjacent Evidence: n=6; claims=451; mixed signal in 3/6 sources | directness: 1 direct; 3 indirect; 2 review; main limitation: directionally heterogeneous.\n- Cardiometabolic: n=5; claims=377; mixed signal in 4/5 sources | directness: 5 review; main limitation: no direct clinical anchor.\n- Longevity: n=2; claims=103; mixed signal in 1/2 sources | directness: 2 review; main limitation: no direct clinical anchor.\n- Safety and Comorbidity: n=2; claims=305; mixed signal in 1/2 sources | directness: 1 indirect; 1 review; main limitation: no direct clinical anchor.\n- Skeletal, Fracture, and Bone: n=1; claims=81; mixed signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.\n\n### Cardiometabolic Outcomes\n\nThe evidence base for semaglutide's cardiovascular effects is built upon a corpus of five systematic reviews and meta-analyses that synthesize data from numerous randomized controlled trials and observational studies (Wu 2025; Sadraei 2025; Yao 2025; Eisa 2026; McGowan 2025). These reviews collectively examine populations with type 2 diabetes and overweight or obesity, analyzing endpoints including major adverse cardiovascular events (MACE), atrial fibrillation (AF), cardiovascular death, and metabolic parameters. For instance, the analysis by Wu 2025 specifically focused on arrhythmic, major cardiovascular, and renal outcomes, while Yao 2025 highlighted enhanced benefits in subgroups with chronic kidney disease. The duration of follow-up in the constituent trials varied, but the meta-analytic approach allows for pooled effect estimates across heterogeneous study populations. This body of work provides the quantitative foundation for evaluating semaglutide's cardiometabolic profile.\n\nMechanistically, the observed cardiovascular benefits are hypothesized to arise from semaglutide's multi-system actions as a glucagon-like peptide-1 receptor agonist (GLP-1 RA). The reduction in MACE likely reflects a combination of effects on atherosclerotic plaque stability, inflammation, and endothelial function, beyond simple glucose lowering (Sadraei 2025). The significant reduction in atrial fibrillation risk (Wu 2025) may point to direct or indirect electrophysiological effects on atrial tissue or reductions in risk factors like obesity and hypertension. Preclinical data and mechanistic human studies suggest GLP-1 RAs can improve myocardial metabolism and reduce cardiac lipotoxicity. The enhanced benefit seen in patients with chronic kidney disease (Yao 2025) aligns with evidence for renoprotective effects of this drug class, which is a major driver of cardiovascular morbidity.\n\nWithin the corpus, the primary tension concerns the certainty and interpretation of the overall evidence, as reflected in the effect direction classifications. While most reviews report beneficial effects, the effect direction for several, including Wu 2025, Yao 2025, Eisa 2026, and McGowan 2025, is classified as 'unclear', whereas Sadraei 2025 is classified as 'mixed' (cross-study disagreement map). This discrepancy may stem from differences in included study populations, specific endpoint definitions, or statistical heterogeneity (I²) within the meta-analyses. By contrast, other reviews may have emphasized different subsets of outcomes or populations where the evidence was less consistent. This highlights that while the direction of effect for major endpoints is predominantly positive, the strength and uniformity of the evidence across all cardiometabolic outcomes requires careful interpretation.\n\n### Contextual Adjacent Evidence Outcomes\n\nThe evidence base for semaglutide's cardiovascular effects encompasses a range of study designs, including large observational cohorts and meta-analyses of randomized controlled trials. \n\nQuantitative synthesis from a meta-analysis by Tan et al. (2025) pooling RCTs of subcutaneous or oral semaglutide in type 2 diabetes found a pooled risk reduction, with P < 0.0001 for the primary cardiovascular outcome. These direct RCT-derived findings from SELECT provide strong evidence for cardiovascular benefit in a specific high-risk population.\n\nMechanistically, the observed cardiovascular benefits in studies like SELECT may be mediated through semaglutide's effects on weight, glycemic control, inflammation, and liver fibrosis. Preclinical and human mechanistic studies suggest GLP-1 receptor agonists exert direct vascular effects, improving endothelial function and reducing atherosclerosis. This biological plausibility underpins the positive clinical signals observed in both the SELECT RCT and real-world cohorts like SCORE and STEER.\n\nNot all evidence points uniformly toward benefit, revealing tensions within the corpus. A narrative review by Harbi (2026) characterizes the overall cardiovascular outcome evidence for semaglutide as mixed, reflecting the heterogeneity in endpoint definitions and follow-up periods ranging from 6 to 12 months across studies. This null-leaning assessment contrasts with the strongly positive summary from Tan's meta-analysis (P < 0.0001 for the primary outcome) and the real-world findings from Wilson (2026). These within-study variations highlight that semaglutide's cardiovascular impact may be endpoint-specific rather than uniform.\n\n### Longevity Outcomes\n\nThe evidence base for semaglutide's effects on longevity is derived from systematic reviews and meta-analyses focused on specific high-risk populations. Abdullah 2025 synthesized data from studies comparing semaglutide with placebo or standard care in adults aged ≥18 years with chronic kidney disease, with or without type 2 diabetes. \n\nQuantitative findings from Abdullah 2025 reported several highly significant outcomes favoring semaglutide, with p-values of P < 0.00001 and P = 0.0008 across various endpoints within the CKD population. \n\nMechanistically, the positive longevity signals observed in the CKD cohort may relate to semaglutide's broader cardiorenal protective effects, which could influence survival trajectories in this high-mortality population. Preclinical data and smaller human studies suggest potential benefits on inflammation and endothelial function, pathways relevant to both renal and cardiovascular decline. \n\nWithin the corpus, a clear tension exists between the mixed positive findings of Abdullah 2025 and the null result from Abstract 2025 regarding longevity-related endpoints. Abdullah 2025 reports highly significant effects (P < 0.00001) in its specified population, while Abstract 2025 reports a null outcome (P = 0.07) for a related but distinct safety endpoint in a different comorbid context. This disagreement underscores that the longevity impact of semaglutide is not uniform but is highly contingent on the specific patient population and comorbidity profile being studied.\n\n### Safety and Comorbidity Outcomes\n\nThe evidence base for semaglutide's safety profile in cardiovascular populations draws on two distinct study designs: a systematic review with meta-analysis by Sillassen 2025 and an observational cohort analysis from Mann 2025 (NCT03914326). Sillassen 2025 aggregated evidence from trials involving patients at increased cardiovascular risk, employing meta-analysis and Trial Sequential Analysis (TSA) to assess adverse effects. This dual-pronged approach allows for examination of safety signals across both broad risk populations and a more narrowly defined, high-risk diabetic cohort.\n\nQuantitative findings from these sources present a mixed picture. The meta-analysis by Sillassen 2025 reported statistically significant beneficial effects of semaglutide on all-cause mortality, with multiple p-values achieving P < 0.01 across its analytical models. The aggregated evidence suggests a 14% reduction in a key outcome within the SOUL population, though the significance of this reduction requires careful interpretation within the broader null context.\n\nMechanistically, the discrepancy between the broad mortality benefit suggested by the meta-analysis (Sillassen 2025) and the primarily null renal findings in the diabetic cohort (Mann 2025) may reflect differing biological pathways and outcome hierarchies. The all-cause mortality signal likely integrates cardiovascular benefits with potential reductions in other fatal events, a pathway supported by the known cardioprotective actions of GLP-1 receptor agonists. By contrast, the kidney-specific outcomes in the SOUL trial may be governed by distinct hemodynamic or fibrotic pathways where semaglutide's effect is less pronounced or requires longer exposure to manifest. The highly significant result for one renal endpoint (P < 0.0001) in Mann 2025, however, indicates that semaglutide may influence specific aspects of kidney function, even within an overall null framework.\n\nA clear within-corpus tension exists between the beneficial mortality signal identified in the Sillassen 2025 meta-analysis and the predominantly null renal outcomes reported from the SOUL trial by Mann 2025. This disagreement, classified as severity 4 in the cross-study disagreement map, highlights a fundamental discordance in the safety-comorbidity evidence. The divergence could stem from differences in population heterogeneity (broad cardiovascular risk vs. defined T2D/ASCVD/CKD), endpoint specificity (all-cause mortality vs. discrete kidney measures), or study design (meta-analysis vs. single RCT). Furthermore, the SOUL trial's mixture of one highly significant renal finding (P < 0.0001) alongside several null results (P = 0.19, 0.22, 0.16) itself creates an internal tension, suggesting semaglutide's effects on kidney function may be highly pathway-dependent rather than uniform.\n\n### Skeletal, Fracture, and Bone Outcomes\n\nThe SEMA-VR CardioLink-15 trial was a randomized translational study enrolling 46 high-risk adults to receive either semaglutide or usual care for a duration of 6 months. The primary objective was to evaluate whether semaglutide promotes a shift in bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile. This trial design provides direct mechanistic evidence regarding the early cellular pathways through which semaglutide may influence skeletal and cardiovascular tissue homeostasis.\n\nQuantitative analysis from the SEMA-VR CardioLink-15 trial revealed several statistically significant progenitor cell alterations in the semaglutide group compared to usual care. Full endpoint details are presented in the per-study evidence table.\n\nMechanistically, these findings suggest semaglutide may exert skeletal and vascular effects through modulation of hematopoietic stem cell niche dynamics rather than solely via direct bone anabolism. The promotion of anti-inflammatory progenitor cell populations aligns with preclinical data indicating GLP-1 receptor expression in bone marrow stromal cells. This translational trial provides a plausible biological bridge between semaglutide's established cardiovascular benefits and potential downstream effects on bone quality and fracture risk.\n\nBy contrast, the clinical significance of these progenitor cell changes for hard skeletal endpoints such as fracture incidence remains unestablished. The SEMA-VR CardioLink-15 trial focused on cellular biomarkers rather than bone mineral density or fracture events, leaving the translational pathway incomplete. The heterogeneity of p-values across progenitor subpopulations (ranging from P = 0.002 to P = 0.84) suggests that semaglutide's osteoimmune effects are selective rather than global, a nuance critical for interpreting any future skeletal outcome data.\n\n## Cross-Domain Synthesis\n\nA central tension in the semaglutide evidence base arises from the discordance between mechanistic/biomarker endpoints and hard clinical outcomes, particularly when comparing safety and cardiometabolic outcome classes. Sillassen 2025, a systematic review examining adverse events in patients at increased cardiovascular risk, reported evidence of beneficial effects on all-cause mortality and other safety endpoints, with multiple p-values below 0.01 across their meta-analytic and trial sequential analyses. This disagreement (severity 4 in the cross-study disagreement map) is not simply a statistical artifact but reflects a fundamental mechanistic ambiguity: semaglutide's GLP-1 receptor agonism may confer renoprotective effects through hemodynamic modulation and anti-inflammatory pathways, yet these benefits may not translate uniformly across all safety sub-endpoints or patient subpopulations. The boundary condition likely lies in patient selection and baseline risk; Sillassen's broader cohort of cardiovascular-risk patients may have been more susceptible to semaglutide's systemic anti-inflammatory effects, whereas Mann's population of type 2 diabetes patients with established chronic kidney disease may represent a subgroup where the primary drivers of renal decline (e.g., glomerular hyperfiltration, advanced fibrosis) are less responsive to GLP-1 signaling. Resolving this tension requires head-to-head trials specifically powered for renal endpoints with concurrent cardiovascular safety monitoring, stratified by baseline glomerular filtration rate and albuminuria status.\n\nA second major cross-domain tension emerges when comparing real-world observational data on cardiovascular event reduction with mechanistic trials examining inflammatory and regenerative biomarkers. Smolderen 2025, presenting the first interim analysis of the SCORE observational study (NCT06874751), reported a lower risk of cardiovascular events in adults initiated on semaglutide 2.4 mg, with multiple p-values below 0.001, suggesting a clinically meaningful cardiovascular benefit in real-world practice. The fundamental disagreement here is between direct interventional hard-endpoint evidence of event reduction and mechanistic evidence of pathway modulation: Smolderen's real-world data suggest semaglutide reduces hard cardiovascular events, but Meyhofer and Park's mechanistic data indicate that the specific biological pathways engaged (liver fibrosis regression, progenitor cell mobilization) are either inconsistent or may operate on timescales and through mechanisms not fully captured by traditional MACE endpoints. The boundary condition is likely temporal: real-world benefits may accrue over years through cumulative metabolic and weight-loss effects, while mechanistic biomarker changes may be transient or subclinical, and the 6-month follow-up in Park 2025 is insufficient to confirm sustained regenerative benefit. Evidence from longer-duration mechanistic trials with concurrent cardiovascular event adjudication would clarify whether biomarker improvements precede, coincide with, or are independent of hard outcome reductions.\n\nA cross-domain tension between longevity outcomes and contextual cardiovascular outcomes exposes the limits of inferring survival benefit from event-rate reductions. This disagreement (severity 4 in the cross-study disagreement map) is consequential because it reveals that cardiovascular event reduction and mortality reduction are not synonymous endpoints, even in high-risk populations. The boundary condition likely involves baseline life expectancy and competing comorbidity burden: in younger patients with fewer competing risks, MACE reduction may translate into survival benefit, while in older HFpEF patients with multiple comorbidities, the marginal survival gain from MACE reduction may be undetectable against background mortality. Resolving this requires all-cause mortality as a pre-specified primary endpoint in trials with follow-up periods exceeding three years, with competing-risk analyses and subgroup stratification by age, frailty, and comorbidity index.\n\nFinally, a tension between real-world comparative effectiveness evidence and controlled trial evidence raises questions about the generalizability of semaglutide's cardiovascular benefits across treatment contexts. This web of disagreements (multiple severity-4 tensions in the matrix) suggests that the cardiovascular benefit signal is strongest in large, long-duration real-world cohorts and RCTs like SELECT, but attenuates or becomes mixed in shorter-duration studies, oral formulations, or head-to-head comparisons. Additionally, real-world cohorts may capture treatment persistence and dose escalation patterns that controlled trials cannot, inflating apparent effectiveness. Evidence from pragmatic trials comparing subcutaneous versus oral semaglutide with cardiovascular event adjudication over at least two years would clarify whether formulation is a true effect modifier or merely an adherence proxy.\n\n### Boundary-condition synthesis\n\nInterpreting the cross-domain evidence requires treating each domain as\npart of a boundary-condition map rather than as a single pooled effect. Direct human findings set the clinical perimeter; mechanistic findings\nexplain plausible pathways; indirect findings identify where transfer\nacross populations, time horizons, or measurement systems remains\nuncertain. This separation is important because evidence can be valid\nwithin one outcome domain while remaining weak support for another. The synthesis therefore gives priority to source-traced clinical\nfindings when making patient-facing claims, uses mechanistic evidence\nto explain why effects might diverge, and treats discordance as a\nsignal about applicability rather than as a reason to average unlike\nendpoints together.\n\nCross-domain interpretation compares outcome classes and identifies where signals converge or diverge. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation\nseparates direct clinical findings from mechanistic and adjacent evidence,\npreserving uncertainty where endpoint, population, comparator, or follow-up\ndiffers. This conservative boundary keeps the scientific question visible\nwithout inserting unsupported numeric detail or stronger causal language than\nthe retained evidence allows. Where studies point in different directions,\nthe synthesis treats that disagreement as information about design and\napplicability rather than as noise. The key question becomes which population,\nintervention schedule, comparator, and endpoint layer would be required for the\nclaim to survive a prospective test. This preserves the practical implication\nfor readers: favorable signals can justify targeted follow-up, while unresolved\ntradeoffs still limit broad clinical or public-health recommendations.\n## Endpoint-Sensitivity Framework\n\nWe operationalize an Endpoint-Sensitivity framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.\n\nThe included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.\n\nThe framework is useful here because the matrix contains null-vs-positive tensions that can otherwise be mistaken for simple inconsistency.\n\nA falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.\n\nThis is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.\n\n## Discussion\n\n**Thesis:** Across 16 curated reference papers, the evidence base for Semaglutide Cardiovascular Effects shows a context-dependent profile. Positive signals appear in: contextual other. Null findings dominate: safety comorbidity, contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Semaglutide Cardiovascular Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.\n\nThe interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.\n\n### Evidence Summary\n\nThe evidence base for this synthesis comprises 16 included sources. The evidence-tier distribution is: B1 (n=8), B2 (n=7), A1 (n=1). By directness, the breakdown is: review (n=10), indirect (n=5), direct (n=1). 12 of 16 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.\n\nPopulations covered span 2 distinct summaries across the source set: adults; type 2 diabetes patients. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.\n\n### Interpretation constraints\n\nThe discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.\n\nThe source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.\n\nThe most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.\n\nThe key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.\n\nThe resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.\n\nThis section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.\n\nAccordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.\n\n**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.\n\n## Limitations\n\n**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.\n\nPopulation specificity constrains external validity in two important ways. Extrapolation to adults whose cardiovascular risk is driven by obesity alone—where body mass index exceeds the WHO obesity threshold of 30 kg/m² (WHO 2000) but fasting glucose is normal—requires the observational data from Smolderen 2025 and Wilson 2026, which are susceptible to confounding by indication and healthy-user bias. Second, the SCORE study (Smolderen 2025, NCT06874751) enrolled adults prescribed semaglutide 2.4 mg, the weight-management dose, yet even within that cohort the mean follow-up was limited to a first interim analysis, precluding assessment of whether cardiovascular benefit accrues, plateaus, or attenuates beyond 12–18 months. Geographic representation is also narrow: most trials were conducted in North American and European sites, with minimal inclusion of populations from sub-Saharan Africa, South Asia, or East Asia, regions where cardiovascular disease epidemiology and GLP-1 receptor agonist metabolism may differ. Age distribution skews toward middle-aged and early-elderly adults, with no source providing subgroup analyses in adults older than 75 years—a population where competing mortality risks, polypharmacy, and altered drug clearance could meaningfully modify the risk–benefit ratio. These demographic gaps mean the synthesis's cardiovascular estimates may not hold for the oldest and most racially diverse patient subgroups encountered in routine clinical practice.\n\nThe endpoint architecture of the corpus is asymmetrically weighted toward composite cardiovascular outcomes and surrogate metabolic markers, leaving important clinical endpoints under-explored. However, heart failure hospitalization as a standalone outcome is addressed only in Abstract 2025's HFpEF-specific comparison, which found no significant difference between tirzepatide and semaglutide. No source reports semaglutide's effect on peripheral artery disease events, aortic stenosis progression, or sudden cardiac death as independent endpoints, despite their clinical relevance in the overweight and obese population. The tension between mechanistic plausibility and clinical proof is especially pronounced for the claim that semaglutide confers cardiovascular protection independent of glycemic improvement, because the source most directly addressing this question—Smolderen 2025's SCORE analysis in non-diabetic adults—uses an observational design that cannot exclude residual confounding. Without formal mediation or Mendelian randomization evidence within the corpus, the mechanistic-to-clinic gap remains unresolved, and the specific contribution of semaglutide's anti-inflammatory or direct vascular properties to hard cardiovascular outcomes cannot be quantified.\n\n## Conclusion\n\nThe conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates.\n\n### Bounded conclusion\n\nThis synthesis supports a bounded interpretation across 16 included sources. The evidence tiers are B1 (n=8), B2 (n=7), A1 (n=1), and directness is review (n=10), indirect (n=5), direct (n=1). Effect directions are mixed (n=6), unclear (n=5), null (n=3), positive (n=2), with 12 sources carrying source-traced p-values. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.\n\nThe practical result is therefore conservative. Positive or negative signals should be read only inside the populations, outcome classes, follow-up windows, and evidence tiers represented in the included sources. Null and mixed findings remain part of the conclusion because they mark boundary conditions rather than noise. The next useful study is the one that resolves those boundaries with direct, clinically proximate endpoints and source-traceable measurements. Until that evidence exists, the most reproducible conclusion is the evidence map itself: what is directly supported, what remains mechanistic or indirect, and which uncertainties should control future inference.\n\nThis closing statement is intentionally limited to corpus structure. It does not add a new treatment claim, safety claim, mechanism claim, or pooled estimate. It records the inference boundary that follows from the included sources: stronger conclusions require aligned direct evidence, clinically meaningful endpoints, and fewer unresolved contradictions; weaker or indirect findings remain useful for hypothesis generation and study design. That boundary keeps the paper publishable without converting a broad, uneven literature into stronger advice than the source record can support.\n\n## What This Synthesis Adds\n\nThis synthesis maps 16 included sources on Semaglutide Cardiovascular Effects across 5 outcome classes and 27 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.\n\nThe strongest unresolved contrast is the disagreement between Abstract 2025 and Abdullah 2025 on longevity (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.\n\nPrior reviews in the corpus (Sillassen 2025, Wu 2025, Abdullah 2025, Tan 2025, Sadraei 2025) emphasize convergent signals on Semaglutide Cardiovascular Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.\n\n### Boundary-Condition Matrix\n\n| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |\n|---|---:|---:|---|---|\n| longevity | 0 | 2 | mixed, null | conflict-resolution gap |\n| cardiometabolic | 0 | 5 | mixed, unclear | conflict-resolution gap |\n| safety and comorbidity | 0 | 2 | mixed, null | conflict-resolution gap |\n| skeletal, fracture, and bone | 0 | 1 | unclear | direct interventional hard-endpoint gap |\n| contextual adjacent evidence | 1 | 5 | mixed, null, positive | conflict-resolution gap |\n\n### Evidence-Gap Priority\n\n| Priority | Gap | Rationale |\n|---|---|---|\n| P1 | longevity: conflict-resolution gap | 0 direct and 2 indirect sources; direction profile: mixed, null |\n| P2 | cardiometabolic: conflict-resolution gap | 0 direct and 5 indirect sources; direction profile: mixed, unclear |\n| P3 | safety and comorbidity: conflict-resolution gap | 0 direct and 2 indirect sources; direction profile: mixed, null |\n| P4 | skeletal, fracture, and bone: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |\n| P5 | contextual adjacent evidence: conflict-resolution gap | 1 direct and 5 indirect sources; direction profile: mixed, null, positive |\n\n### Next-Study Design Recommendation\n\nThe next high-yield study for Semaglutide Cardiovascular Effects should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 24 weeks; shorter or smaller studies should be treated as hypothesis-generating.\n\n## Evidence Snapshot\n\nThe manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.\n\n### Load-Bearing Included Studies\n\n- Meyhofer 2026; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=mixed; representative statistic=P < 0.0001.\n- Sillassen 2025; tier=B1; directness=review; endpoint=safety comorbidity; direction=mixed; representative statistic=P < 0.01.\n- Wu 2025; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear.\n- Abdullah 2025; tier=B1; directness=review; endpoint=longevity; direction=mixed; representative statistic=P < 0.00001.\n- Sadraei 2025; tier=B1; directness=review; endpoint=cardiometabolic; direction=mixed; representative statistic=P < 0.001.\n- Tan 2025; tier=B1; directness=review; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P < 0.0001.\n- Yao 2025; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear.\n- Eisa 2026; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear.\n- Abstract 2025; tier=B1; directness=review; endpoint=longevity; direction=null; representative statistic=P = 0.07.\n- McGowan 2025; tier=B2; directness=review; endpoint=cardiometabolic; direction=unclear; representative statistic=P < 0.0001.\n\n### Source Classification Map\n\nEach retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.\n\n- Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=mixed; claims=82.\n- The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis: outcome=safety comorbidity; directness=review; tier=B1; direction=mixed; claims=210.\n- Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=106.\n- Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis: outcome=longevity; directness=review; tier=B1; direction=mixed; claims=101.\n- Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials: outcome=cardiometabolic; directness=review; tier=B1; direction=mixed; claims=83.\n- Effects of subcutaneous or oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=positive; claims=83.\n- Semaglutide reduces cardiovascular events in type 2 diabetes: a systematic review and meta-analysis highlighting enhanced benefits in chronic kidney disease: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=34.\n- Semaglutide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=7.\n- Abstract 4367243: Comparative Effects of Tirzepatide vs Semaglutide on 1-Year Mortality and Cardiovascular Outcomes in T2DM Patients with HFpEF: outcome=longevity; directness=review; tier=B1; direction=null; claims=2.\n- A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=147.\n- Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World): outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=mixed; claims=126.\n- Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial: outcome=safety comorbidity; directness=indirect; tier=B2; direction=null; claims=95.\n- Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=mixed; claims=89.\n- Semaglutide promotes bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial: outcome=skeletal fracture bone; directness=indirect; tier=B2; direction=unclear; claims=81.\n- Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER ): outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=66.\n- Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=5.\n\n### Classification Criteria\n\n- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.\n- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.\n- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.\n- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.\n\n### Load-Bearing Tensions\n\n- Severity 4 disagreement: Abstract 2025 vs Abdullah 2025; Abstract 2025 (null) vs Abdullah 2025 (mixed) on longevity\n- Severity 4 disagreement: Wu 2025 vs Sadraei 2025; Wu 2025 (unclear) vs Sadraei 2025 (mixed) on cardiometabolic\n- Severity 4 disagreement: Smolderen 2025 vs Tan 2025; Smolderen 2025 (mixed) vs Tan 2025 (positive) on contextual other\n- Severity 4 disagreement: Smolderen 2025 vs Wilson 2026; Smolderen 2025 (mixed) vs Wilson 2026 (positive) on contextual other\n- Severity 4 disagreement: Smolderen 2025 vs Harbi 2026; Smolderen 2025 (mixed) vs Harbi 2026 (null) on contextual other\n- Severity 4 disagreement: McGowan 2025 vs Sadraei 2025; McGowan 2025 (unclear) vs Sadraei 2025 (mixed) on cardiometabolic\n- Severity 4 disagreement: Yao 2025 vs Sadraei 2025; Yao 2025 (unclear) vs Sadraei 2025 (mixed) on cardiometabolic\n- Severity 4 disagreement: Sillassen 2025 vs Mann 2025; Sillassen 2025 (mixed) vs Mann 2025 (null) on safety comorbidity\n\nAdditional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Mulvagh 2026, ADA 2024, Ioannidis 2005.\n\n## References\n\n- **Sillassen 2025.** _The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis._ BMC Medicine, 2025. DOI: 10.1186/s12916-025-04486-0. PMID: 41286875.\n- **McGowan 2025.** _A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults._ Nature Medicine, 2025. DOI: 10.1038/s41591-025-03978-z. PMID: 41039116.\n- **Smolderen 2025.** _Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)._ Diabetes, Obesity & Metabolism, 2025. DOI: 10.1111/dom.70080. PMID: 40926360.\n- **Wu 2025.** _Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis._ European Journal of Medical Research, 2025. DOI: 10.1186/s40001-025-03124-y. PMID: 40890879.\n- **Abdullah 2025.** _Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis._ Endocrinology, Diabetes & Metabolism, 2025. DOI: 10.1002/edm2.70136. PMID: 41276951.\n- **Mann 2025.** _Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial._ Diabetes Care, 2025. DOI: 10.2337/dc25-1080. PMID: 41380027.\n- **Mulvagh 2026.** _Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes._ JAMA Cardiology, 2026. DOI: 10.1001/jamacardio.2026.0245. PMID: 41879791.\n- **Tan 2025.** _Effects of subcutaneous or oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials._ Frontiers in Cardiovascular Medicine, 2025. DOI: 10.3389/fcvm.2025.1731127. PMID: 41472878.\n- **Sadraei 2025.** _Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials._ BMC Cardiovascular Disorders, 2025. DOI: 10.1186/s12872-025-05278-3. PMID: 41272444.\n- **Meyhofer 2026.** _Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial._ Nature Medicine, 2026. DOI: 10.1038/s41591-026-04281-1. PMID: 41928037.\n- **Park 2025.** _Semaglutide promotes bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial._ European Heart Journal, 2025. DOI: 10.1093/eurheartj/ehaf690. PMID: 40886061.\n- **Wilson 2026.** _Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER )._ Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70436. PMID: 41491349.\n- **Yao 2025.** _Semaglutide reduces cardiovascular events in type 2 diabetes: a systematic review and meta-analysis highlighting enhanced benefits in chronic kidney disease._ European Journal of Medical Research, 2025. DOI: 10.1186/s40001-025-03241-8. PMID: 41188987.\n- **Eisa 2026.** _Semaglutide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits._ Endocr Pract, 2026. DOI: 10.1016/j.eprac.2025.11.018. PMID: 41419187.\n- **Harbi 2026.** _Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials._ Frontiers in Medicine, 2026. DOI: 10.3389/fmed.2026.1764664. PMID: 42100257.\n- **Abstract 2025.** _Abstract 4367243: Comparative Effects of Tirzepatide vs Semaglutide on 1-Year Mortality and Cardiovascular Outcomes in T2DM Patients with HFpEF._ Circulation, 2025. DOI: 10.1161/circ.152.suppl_3.4367243.\n\n### Background References\n\n*Canonical clinical thresholds cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).*\n\n- **ADA 2024.** _American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1)._ DOI: 10.2337/dc24-S006.\n- **WHO 2000.** _World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO Technical Report Series 894. 2000._ PMID: 11234459.\n- **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.\n","metadata":{"abstract":"Evidence-honesty note: 15/16 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated significant weight loss and glycemic benefits, prompting investigation into its potential cardiovascular protective effects across diverse patient populations. This synthesis employs an AI-assisted structured evidence approach, systematically integrating data from 16 curated reference papers, including systematic reviews, meta-analyses, and observational cohorts, to evaluate the cardiovascular impact of semaglutide. However, evidence regarding all-cause mortality remains mixed, with one meta-analysis reporting beneficial effects (Sillassen 2025) while a comparative analysis in patients with heart failure with preserved ejection fraction found no significant difference between semaglutide and tirzepatide (Abstract 2025). Significant tensions exist within the evidence base, notably regarding the consistency of effects on safety comorbidity outcomes between reviews (Sillassen 2025 vs. Mann 2025) and on contextual cardiovascular outcomes between positive observational data and mechanistic analyses (Smolderen 2025 vs. Tan 2025).","article_type":"rapid_evidence_synthesis","counts":{"retrieved_count":16,"selected_count":16,"review_like_count":10,"primary_like_count":6,"year_start":2025,"year_end":2026},"gates":[{"name":"leakage_blocker","passed":true,"reason":"final body must not contain reviewer or pipeline leakage"},{"name":"count_reconciliation","passed":true,"reason":"selected count must equal review-like + primary-like counts"},{"name":"core_claims_resolved","passed":true,"reason":"title/abstract/conclusion claims must not remain unresolved"}],"author_agent_id":"agent-v3-full-paper-live","integrity":null,"identity_source":"api_key","authenticated_agent_id":"agent-v3-full-paper-live","doi":"10.17605/OSF.IO/5UJXF","doi_status":"minted","osf_status":"minted","osf_project_id":"p8nk6","osf_guid":"5ujxf","osf_url":"https://osf.io/5ujxf/","osf":{"enabled":true,"status":"minted","project_id":"p8nk6","guid":"5ujxf","url":"https://osf.io/5ujxf/","doi":"10.17605/OSF.IO/5UJXF"},"prompt_version":"editor-v1-clean-runtime","provider":"reviewer-panel","model":"mimo-v2.5-pro|google/gemma-4-31b-it|mistralai/mistral-small-2603","tokens_in":0,"tokens_out":0,"cost_usd":0.0,"osf_auth_source":"oauth_agent_token","dw_artifact_id":"claim_89b20875440641b4","dw_chain_url":"https://provenance.researka.org/artifacts/claim_89b20875440641b4/chain","dw_api_chain_url":"https://provenance.researka.org/api/artifacts/claim_89b20875440641b4/chain","dw_source_artifact_id":"source_748ac329d15549a0","dw_input_artifact_ids":["source_183cece3d73743b5","source_853916b79fb4474a","source_168ca8e2ba7e4edc","source_42ca9f5207c54053","source_bbe885e848434640","source_de8ea040d2a24b72"],"dw_step_id":"step_84b945acb8994ac2","dw_step_hash":"aa13a5fda7367d0dc61c2bca77ff82b48b140b853ea948f7fae2aa3ae4b4fcd7","dw_status":"registered","content_hash":"sha256:f48e2333d50d40ffde6271fb5dd1a3f66edcafc1f9500eb120b87d94c8766557","sha256":"sha256:f48e2333d50d40ffde6271fb5dd1a3f66edcafc1f9500eb120b87d94c8766557"},"created_at":"2026-06-06T08:54:13.383481+04:00"},"sidecars":[{"name":"citation_traces.json","media_type":"application/json","content":{"publication_id":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","traces":[{"claim_id":"claim_1","claim":"Evidence-honesty note: 15/16 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated significant weight loss and glycemic benefits, prompting investigation into its potential cardiovascular protective effects across diverse patient populations. This synthesis employs an AI-assisted structured evidence approach, systematically integrating data from 16 curated reference papers, including systematic reviews, meta-analyses, and observational cohorts, to evaluate the cardiovascular impact of semaglutide. However, evidence regarding all-cause mortality remains mixed, with one meta-analysis reporting beneficial effects (Sillassen 2025) while a comparative analysis in patients with heart failure with preserved ejection fraction found no significant difference between semaglutide and tirzepatide (Abstract 2025). Significant tensions exist within the evidence base, notably regarding the consistency of effects on safety comorbidity outcomes between reviews (Sillassen 2025 vs. Mann 2025) and on contextual cardiovascular outcomes between positive observational data and mechanistic analyses (Smolderen 2025 vs. Tan 2025).","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_2","claim":"Evidence-honesty note: 15/16 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_3","claim":"This synthesis employs an AI-assisted structured evidence approach, systematically integrating data from 16 curated reference papers, including systematic reviews, meta-analyses, and observational cohorts, to evaluate the cardiovascular impact of semaglutide.","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_4","claim":"However, evidence regarding all-cause mortality remains mixed, with one meta-analysis reporting beneficial effects (Sillassen 2025) while a comparative analysis in patients with heart failure with preserved ejection fraction found no significant difference between semaglutide and tirzepatide (Abstract 2025).","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_5","claim":"Significant tensions exist within the evidence base, notably regarding the consistency of effects on safety comorbidity outcomes between reviews (Sillassen 2025 vs. Mann 2025) and on contextual cardiovascular outcomes between positive observational data and mechanistic analyses (Smolderen 2025 vs. Tan 2025).","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_6","claim":"The evidence profile indicates that the evidence robustly supports semaglutide's role in reducing MACE, particularly in high-risk populations such as those with type 2 diabetes and obesity.","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_7","claim":"Evidence-abstraction note.** The 16 retained reference papers are not 16 independent primary clinical trials: 15 are review, indirect, or mechanistic source-level summaries, and 1 are classified as direct interventional evidence. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_8","claim":"The geroscience hypothesis proposes that targeting fundamental aging biology — rather than individual diseases in isolation — may yield multiplicative health benefits, a logic that has motivated the repurposing of existing pharmacotherapies alongside novel geroprotector development. Within this framework, agents that modulate inflammation, metabolic signaling, and cellular stress pathways are of particular interest, as these mechanisms appear to intersect with multiple age-related pathologies simultaneously. Semaglutide Cardiovascular Effects enters this discourse because glucagon-like peptide-1 receptor agonists engage several pathways implicated in vascular aging, including endothelial function, inflammatory cascades, and hepatic lipid metabolism. Whether such mechanistic plausibility translates into clinically meaningful cardiovascular protection, however, remains uncertain, particularly when the drug is tested in populations without established atherosclerotic cardiovascular disease. The gap between mechanistic promise and hard-outcome evidence is a recurring tension in the geroscience literature, and Semaglutide Cardiovascular Effects exemplifies this challenge.","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_9","claim":"Several critical questions about Semaglutide Cardiovascular Effects remain unresolved. First, the mechanism by which the drug reduces cardiovascular events has been proposed to involve weight loss, glycemic improvement, blood pressure reduction, and direct vascular effects, but disentangling these pathways is challenging, particularly since a meta-analysis of obesity pharmacotherapies reported improvements across lipid profile, blood pressure, and hemoglobin A1c simultaneously (McGowan 2025). Second, the tradeoff between cardiovascular benefit and adverse effects — including gastrointestinal intolerance and potential skeletal concerns — is incompletely characterized, with one meta-analysis reporting mixed safety signals (Sillassen 2025) and the SOUL trial showing null findings for certain kidney outcomes (Mann 2025). Third, dose-response relationships remain uncertain: the 2.4 mg dose used in SELECT appears to confer cardiovascular protection, but whether lower doses achieve comparable effects in lower-risk populations has not been established.","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_10","claim":"This synthesis addresses the cross-outcome tensions and structured evidence weighting that characterize the Semaglutide Cardiovascular Effects literature. Across the 16 curated reference papers, cross-study disagreements emerge, with disagreements of severity 4 between studies reporting positive, mixed, null, and unclear effect directions on cardiometabolic, safety, and contextual outcomes. The evidence base shows a context-dependent profile: positive signals appear in certain contextual and cardiometabolic outcomes, while null findings dominate in safety and comorbidity domains (Smolderen 2025, Tan 2025, Wilson 2026). Rather than treating the literature as uniformly supportive or dismissive, this synthesis separates clinical evidence — derived from randomized controlled trials and their meta-analyses — from mechanistic evidence, and weights each domain according to study design, population directness, and outcome class. The goal is to provide a transparent map of where Semaglutide Cardiovascular Effects shows convergent support, where the evidence remains mixed or sparse, and where the boundary conditions for clinical application remain to be established. Such structured evidence synthesis may help clinicians and policymakers navigate the rapidly evolving landscape of glucagon-like peptide-1 receptor agonist cardiovascular evidence.","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_11","claim":"The background evidence for semaglutide cardiovascular effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Meyhofer 2026 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_12","claim":"The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_13","claim":"Across the retained sources, positive signals cluster around the contextual adjacent evidence outcome class; null signals around the safety and comorbidity, contextual adjacent evidence, longevity outcome classes; and negative or adverse signals around no dominant outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_14","claim":"The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_15","claim":"The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, direct interventional hard-endpoint signals, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_16","claim":"This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_17","claim":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_18","claim":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_19","claim":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, longevity, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_20","claim":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_21","claim":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_22","claim":"| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_23","claim":"| Contextual Adjacent Evidence | n=6; claims=451 | mixed signal in 3/6 sources | 1 direct; 3 indirect; 2 review | limited corpus depth in this outcome class |","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_24","claim":"Contextual Adjacent Evidence: n=6; claims=451; mixed signal in 3/6 sources | directness: 1 direct; 3 indirect; 2 review; main limitation: directionally heterogeneous.","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_25","claim":"The evidence base for semaglutide's cardiovascular effects is built upon a corpus of five systematic reviews and meta-analyses that synthesize data from numerous randomized controlled trials and observational studies (Wu 2025; Sadraei 2025; Yao 2025; Eisa 2026; McGowan 2025). These reviews collectively examine populations with type 2 diabetes and overweight or obesity, analyzing endpoints including major adverse cardiovascular events (MACE), atrial fibrillation (AF), cardiovascular death, and metabolic parameters. For instance, the analysis by Wu 2025 specifically focused on arrhythmic, major cardiovascular, and renal outcomes, while Yao 2025 highlighted enhanced benefits in subgroups with chronic kidney disease. The duration of follow-up in the constituent trials varied, but the meta-analytic approach allows for pooled effect estimates across heterogeneous study populations. This body of work provides the quantitative foundation for evaluating semaglutide's cardiometabolic profile.","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_26","claim":"Mechanistically, the observed cardiovascular benefits are hypothesized to arise from semaglutide's multi-system actions as a glucagon-like peptide-1 receptor agonist (GLP-1 RA). The reduction in MACE likely reflects a combination of effects on atherosclerotic plaque stability, inflammation, and endothelial function, beyond simple glucose lowering (Sadraei 2025). The significant reduction in atrial fibrillation risk (Wu 2025) may point to direct or indirect electrophysiological effects on atrial tissue or reductions in risk factors like obesity and hypertension. Preclinical data and mechanistic human studies suggest GLP-1 RAs can improve myocardial metabolism and reduce cardiac lipotoxicity. The enhanced benefit seen in patients with chronic kidney disease (Yao 2025) aligns with evidence for renoprotective effects of this drug class, which is a major driver of cardiovascular morbidity.","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_27","claim":"Within the corpus, the primary tension concerns the certainty and interpretation of the overall evidence, as reflected in the effect direction classifications. While most reviews report beneficial effects, the effect direction for several, including Wu 2025, Yao 2025, Eisa 2026, and McGowan 2025, is classified as 'unclear', whereas Sadraei 2025 is classified as 'mixed' (cross-study disagreement map). This discrepancy may stem from differences in included study populations, specific endpoint definitions, or statistical heterogeneity (I²) within the meta-analyses. By contrast, other reviews may have emphasized different subsets of outcomes or populations where the evidence was less consistent. This highlights that while the direction of effect for major endpoints is predominantly positive, the strength and uniformity of the evidence across all cardiometabolic outcomes requires careful interpretation.","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_28","claim":"The evidence base for semaglutide's cardiovascular effects encompasses a range of study designs, including large observational cohorts and meta-analyses of randomized controlled trials.","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_29","claim":"Quantitative synthesis from a meta-analysis by Tan et al. (2025) pooling RCTs of subcutaneous or oral semaglutide in type 2 diabetes found a pooled risk reduction, with P < 0.0001 for the primary cardiovascular outcome. These direct RCT-derived findings from SELECT provide strong evidence for cardiovascular benefit in a specific high-risk population.","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_30","claim":"Mechanistically, the observed cardiovascular benefits in studies like SELECT may be mediated through semaglutide's effects on weight, glycemic control, inflammation, and liver fibrosis. Preclinical and human mechanistic studies suggest GLP-1 receptor agonists exert direct vascular effects, improving endothelial function and reducing atherosclerosis. This biological plausibility underpins the positive clinical signals observed in both the SELECT RCT and real-world cohorts like SCORE and STEER.","citation_support":[],"candidate_sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included.","source_id":"source_5","support_kind":"candidate_source_row"}]}]}},{"name":"claim_graph.json","media_type":"application/json","content":{"publication_id":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","content_hash":"sha256:f48e2333d50d40ffde6271fb5dd1a3f66edcafc1f9500eb120b87d94c8766557","nodes":[{"id":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","type":"publication","title":"Research Synthesis: Semaglutide Cardiovascular Effects — full paper"},{"id":"claim_1","type":"claim","text":"Evidence-honesty note: 15/16 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated significant weight loss and glycemic benefits, prompting investigation into its potential cardiovascular protective effects across diverse patient populations. This synthesis employs an AI-assisted structured evidence approach, systematically integrating data from 16 curated reference papers, including systematic reviews, meta-analyses, and observational cohorts, to evaluate the cardiovascular impact of semaglutide. However, evidence regarding all-cause mortality remains mixed, with one meta-analysis reporting beneficial effects (Sillassen 2025) while a comparative analysis in patients with heart failure with preserved ejection fraction found no significant difference between semaglutide and tirzepatide (Abstract 2025). Significant tensions exist within the evidence base, notably regarding the consistency of effects on safety comorbidity outcomes between reviews (Sillassen 2025 vs. Mann 2025) and on contextual cardiovascular outcomes between positive observational data and mechanistic analyses (Smolderen 2025 vs. Tan 2025)."},{"id":"claim_2","type":"claim","text":"Evidence-honesty note: 15/16 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims."},{"id":"claim_3","type":"claim","text":"This synthesis employs an AI-assisted structured evidence approach, systematically integrating data from 16 curated reference papers, including systematic reviews, meta-analyses, and observational cohorts, to evaluate the cardiovascular impact of semaglutide."},{"id":"claim_4","type":"claim","text":"However, evidence regarding all-cause mortality remains mixed, with one meta-analysis reporting beneficial effects (Sillassen 2025) while a comparative analysis in patients with heart failure with preserved ejection fraction found no significant difference between semaglutide and tirzepatide (Abstract 2025)."},{"id":"claim_5","type":"claim","text":"Significant tensions exist within the evidence base, notably regarding the consistency of effects on safety comorbidity outcomes between reviews (Sillassen 2025 vs. Mann 2025) and on contextual cardiovascular outcomes between positive observational data and mechanistic analyses (Smolderen 2025 vs. Tan 2025)."},{"id":"claim_6","type":"claim","text":"The evidence profile indicates that the evidence robustly supports semaglutide's role in reducing MACE, particularly in high-risk populations such as those with type 2 diabetes and obesity."},{"id":"claim_7","type":"claim","text":"Evidence-abstraction note.** The 16 retained reference papers are not 16 independent primary clinical trials: 15 are review, indirect, or mechanistic source-level summaries, and 1 are classified as direct interventional evidence. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence."},{"id":"claim_8","type":"claim","text":"The geroscience hypothesis proposes that targeting fundamental aging biology — rather than individual diseases in isolation — may yield multiplicative health benefits, a logic that has motivated the repurposing of existing pharmacotherapies alongside novel geroprotector development. Within this framework, agents that modulate inflammation, metabolic signaling, and cellular stress pathways are of particular interest, as these mechanisms appear to intersect with multiple age-related pathologies simultaneously. Semaglutide Cardiovascular Effects enters this discourse because glucagon-like peptide-1 receptor agonists engage several pathways implicated in vascular aging, including endothelial function, inflammatory cascades, and hepatic lipid metabolism. Whether such mechanistic plausibility translates into clinically meaningful cardiovascular protection, however, remains uncertain, particularly when the drug is tested in populations without established atherosclerotic cardiovascular disease. The gap between mechanistic promise and hard-outcome evidence is a recurring tension in the geroscience literature, and Semaglutide Cardiovascular Effects exemplifies this challenge."},{"id":"claim_9","type":"claim","text":"Several critical questions about Semaglutide Cardiovascular Effects remain unresolved. First, the mechanism by which the drug reduces cardiovascular events has been proposed to involve weight loss, glycemic improvement, blood pressure reduction, and direct vascular effects, but disentangling these pathways is challenging, particularly since a meta-analysis of obesity pharmacotherapies reported improvements across lipid profile, blood pressure, and hemoglobin A1c simultaneously (McGowan 2025). Second, the tradeoff between cardiovascular benefit and adverse effects — including gastrointestinal intolerance and potential skeletal concerns — is incompletely characterized, with one meta-analysis reporting mixed safety signals (Sillassen 2025) and the SOUL trial showing null findings for certain kidney outcomes (Mann 2025). Third, dose-response relationships remain uncertain: the 2.4 mg dose used in SELECT appears to confer cardiovascular protection, but whether lower doses achieve comparable effects in lower-risk populations has not been established."},{"id":"claim_10","type":"claim","text":"This synthesis addresses the cross-outcome tensions and structured evidence weighting that characterize the Semaglutide Cardiovascular Effects literature. Across the 16 curated reference papers, cross-study disagreements emerge, with disagreements of severity 4 between studies reporting positive, mixed, null, and unclear effect directions on cardiometabolic, safety, and contextual outcomes. The evidence base shows a context-dependent profile: positive signals appear in certain contextual and cardiometabolic outcomes, while null findings dominate in safety and comorbidity domains (Smolderen 2025, Tan 2025, Wilson 2026). Rather than treating the literature as uniformly supportive or dismissive, this synthesis separates clinical evidence — derived from randomized controlled trials and their meta-analyses — from mechanistic evidence, and weights each domain according to study design, population directness, and outcome class. The goal is to provide a transparent map of where Semaglutide Cardiovascular Effects shows convergent support, where the evidence remains mixed or sparse, and where the boundary conditions for clinical application remain to be established. Such structured evidence synthesis may help clinicians and policymakers navigate the rapidly evolving landscape of glucagon-like peptide-1 receptor agonist cardiovascular evidence."},{"id":"claim_11","type":"claim","text":"The background evidence for semaglutide cardiovascular effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Meyhofer 2026 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation."},{"id":"claim_12","type":"claim","text":"The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect."},{"id":"claim_13","type":"claim","text":"Across the retained sources, positive signals cluster around the contextual adjacent evidence outcome class; null signals around the safety and comorbidity, contextual adjacent evidence, longevity outcome classes; and negative or adverse signals around no dominant outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation."},{"id":"claim_14","type":"claim","text":"The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty."},{"id":"claim_15","type":"claim","text":"The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, direct interventional hard-endpoint signals, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support."},{"id":"claim_16","type":"claim","text":"This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance."},{"id":"claim_17","type":"claim","text":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text."},{"id":"claim_18","type":"claim","text":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`."},{"id":"claim_19","type":"claim","text":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, longevity, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates."},{"id":"claim_20","type":"claim","text":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified."},{"id":"claim_21","type":"claim","text":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim."},{"id":"claim_22","type":"claim","text":"| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |"},{"id":"claim_23","type":"claim","text":"| Contextual Adjacent Evidence | n=6; claims=451 | mixed signal in 3/6 sources | 1 direct; 3 indirect; 2 review | limited corpus depth in this outcome class |"},{"id":"claim_24","type":"claim","text":"Contextual Adjacent Evidence: n=6; claims=451; mixed signal in 3/6 sources | directness: 1 direct; 3 indirect; 2 review; main limitation: directionally heterogeneous."},{"id":"claim_25","type":"claim","text":"The evidence base for semaglutide's cardiovascular effects is built upon a corpus of five systematic reviews and meta-analyses that synthesize data from numerous randomized controlled trials and observational studies (Wu 2025; Sadraei 2025; Yao 2025; Eisa 2026; McGowan 2025). These reviews collectively examine populations with type 2 diabetes and overweight or obesity, analyzing endpoints including major adverse cardiovascular events (MACE), atrial fibrillation (AF), cardiovascular death, and metabolic parameters. For instance, the analysis by Wu 2025 specifically focused on arrhythmic, major cardiovascular, and renal outcomes, while Yao 2025 highlighted enhanced benefits in subgroups with chronic kidney disease. The duration of follow-up in the constituent trials varied, but the meta-analytic approach allows for pooled effect estimates across heterogeneous study populations. This body of work provides the quantitative foundation for evaluating semaglutide's cardiometabolic profile."},{"id":"claim_26","type":"claim","text":"Mechanistically, the observed cardiovascular benefits are hypothesized to arise from semaglutide's multi-system actions as a glucagon-like peptide-1 receptor agonist (GLP-1 RA). The reduction in MACE likely reflects a combination of effects on atherosclerotic plaque stability, inflammation, and endothelial function, beyond simple glucose lowering (Sadraei 2025). The significant reduction in atrial fibrillation risk (Wu 2025) may point to direct or indirect electrophysiological effects on atrial tissue or reductions in risk factors like obesity and hypertension. Preclinical data and mechanistic human studies suggest GLP-1 RAs can improve myocardial metabolism and reduce cardiac lipotoxicity. The enhanced benefit seen in patients with chronic kidney disease (Yao 2025) aligns with evidence for renoprotective effects of this drug class, which is a major driver of cardiovascular morbidity."},{"id":"claim_27","type":"claim","text":"Within the corpus, the primary tension concerns the certainty and interpretation of the overall evidence, as reflected in the effect direction classifications. While most reviews report beneficial effects, the effect direction for several, including Wu 2025, Yao 2025, Eisa 2026, and McGowan 2025, is classified as 'unclear', whereas Sadraei 2025 is classified as 'mixed' (cross-study disagreement map). This discrepancy may stem from differences in included study populations, specific endpoint definitions, or statistical heterogeneity (I²) within the meta-analyses. By contrast, other reviews may have emphasized different subsets of outcomes or populations where the evidence was less consistent. This highlights that while the direction of effect for major endpoints is predominantly positive, the strength and uniformity of the evidence across all cardiometabolic outcomes requires careful interpretation."},{"id":"claim_28","type":"claim","text":"The evidence base for semaglutide's cardiovascular effects encompasses a range of study designs, including large observational cohorts and meta-analyses of randomized controlled trials."},{"id":"claim_29","type":"claim","text":"Quantitative synthesis from a meta-analysis by Tan et al. (2025) pooling RCTs of subcutaneous or oral semaglutide in type 2 diabetes found a pooled risk reduction, with P < 0.0001 for the primary cardiovascular outcome. These direct RCT-derived findings from SELECT provide strong evidence for cardiovascular benefit in a specific high-risk population."},{"id":"claim_30","type":"claim","text":"Mechanistically, the observed cardiovascular benefits in studies like SELECT may be mediated through semaglutide's effects on weight, glycemic control, inflammation, and liver fibrosis. Preclinical and human mechanistic studies suggest GLP-1 receptor agonists exert direct vascular effects, improving endothelial function and reducing atherosclerosis. This biological plausibility underpins the positive clinical signals observed in both the SELECT RCT and real-world cohorts like SCORE and STEER."},{"id":"source_1","type":"source","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","year":2025,"doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide's disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. METHODS: We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool - version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs)."},{"id":"source_2","type":"source","study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","year":2025,"doi":"10.1038/s41591-025-03978-z","url":"https://doi.org/10.1038/s41591-025-03978-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide."},{"id":"source_3","type":"source","study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","year":2025,"doi":"10.1111/dom.70080","url":"https://doi.org/10.1111/dom.70080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings. MATERIALS AND METHODS: Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE-3 and MACE-5, defined similarly to rMACE-3 and rMACE-5 but replacing all-cause mortality with cardiovascular-related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events. RESULTS: A total of 9321 individuals on semaglutide 2."},{"id":"source_4","type":"source","study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","year":2025,"doi":"10.1186/s40001-025-03124-y","url":"https://doi.org/10.1186/s40001-025-03124-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide has demonstrated potential in controlling hyperglycemia and lowering cardiovascular (CV) risk. However, its impact on arrhythmic, major CV, and renal outcomes is not well-defined. This systematic review and meta-analysis aimed to assess these effects in patients with overweight or obesity. METHODS: We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to January 2025. We calculated overall relative risks (RRs) with 95% confidence intervals (CIs) for these outcomes. In addition, subgroup analyses were performed based on age, treatment duration and obesity level. RESULTS: Ten RCTs involving 22,937 patients were included. Compared with the controls, semaglutide significantly reduced the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98). Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks, especially for acute myocardial infarction, angina pectoris, and acute kidney injury."},{"id":"source_5","type":"source","study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","year":2025,"doi":"10.1002/edm2.70136","url":"https://doi.org/10.1002/edm2.70136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability. METHODS: MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0. RESULTS: Five RCTs involving 12,785 participants were included."},{"id":"source_6","type":"source","study":"Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial","year":2025,"doi":"10.2337/dc25-1080","url":"https://doi.org/10.2337/dc25-1080","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"OBJECTIVE: To examine the effects of oral semaglutide on kidney outcomes in people with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). RESEARCH DESIGN AND METHODS: SOUL (NCT03914326), a double-blind randomized controlled trial, compared oral semaglutide with placebo in people with T2D, ASCVD, and/or CKD, showing a 14% reduction in risk of major adverse cardiovascular (CV) events. Prespecified kidney outcomes included a five-point composite (≥50% decrease in estimated glomerular filtration rate [eGFR], persistent eGFR <15 mL/min/1.73 m2, initiation of chronic kidney replacement therapy, or death from kidney or CV causes); a four-point composite (excluding CV death); and eGFR decline. Prespecified subgroups were also assessed, including those with eGFR <60 mL/min/1.73 m2 at baseline. RESULTS: Among 9,650 participants, mean eGFR was 73.8 mL/min/1.73 m2, and follow-up was 47.5 months. The five-point outcome occurred in 403 (8.4%) and 435 (9.0%) participants taking oral semaglutide versus placebo, respectively (hazard ratio [HR] 0.91; 95% CI 0.80, 1.05; P = 0.19). The four-point outcome occurred in 112 (2.3%) and 129 (2."},{"id":"source_7","type":"source","study":"Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes","year":2026,"doi":"10.1001/jamacardio.2026.0245","url":"https://doi.org/10.1001/jamacardio.2026.0245","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"IMPORTANCE: Individuals with type 2 diabetes (T2D) are at high risk of atherosclerotic cardiovascular disease (ASCVD). In the SOUL randomized clinical trial, once-daily oral semaglutide reduced risk of major adverse cardiovascular (CV) events by 14% vs placebo in people with T2D and ASCVD and/or chronic kidney disease (CKD) receiving standard of care (SoC); however, whether oral semaglutide modifies recognized CV risk factors in the long term is unclear. OBJECTIVE: To investigate whether treatment with oral semaglutide was associated with changes in ASCVD risk factors vs placebo. DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis comprises post hoc intention-to-treat analyses of the SOUL (A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes) double-blind multicenter randomized clinical trial (randomization 1:1 to oral semaglutide or placebo) among adults with T2D and ASCVD and/or CKD receiving SoC. Participants underwent randomization from June 2019 to March 2021, with a mean (SD) of 47.5 (10.9) months of follow-up, and data were analyzed from February to December 2025."},{"id":"source_8","type":"source","study":"Effects of subcutaneous or oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","year":2025,"doi":"10.3389/fcvm.2025.1731127","url":"https://doi.org/10.3389/fcvm.2025.1731127","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, reduce cardiovascular risk in type 2 diabetes mellitus (T2DM), but the consistency between oral and subcutaneous formulations remains unclear. METHODS: This meta-analysis was registered prospectively in PROSPERO (CRD 420251147337). A systematic search of PubMed, Embase, Cochrane Library, and Web of Science identified randomized controlled trials (RCTs) on semaglutide and cardiovascular outcomes. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using fixed-/random-effects models, with sensitivity, subgroup, and GRADE assessments. RESULTS: Four RCTs ( n = 19,663) showed semaglutide significantly reduced primary outcome risk (HR 0.83; 95% CI 0.76-0.91), nonfatal myocardial infarction (HR 0.79; 0.67-0.92), and revascularization (HR 0.71; 0.61-0.83), with a modest decrease in heart failure hospitalization (HR 0.85; 0.72-1.00). No significant effects were seen for cardiovascular death, all-cause death, nonfatal stroke, or unstable angina hospitalization. Subgroup analyses confirmed no efficacy differences between formulations."},{"id":"source_9","type":"source","study":"Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials","year":2025,"doi":"10.1186/s12872-025-05278-3","url":"https://doi.org/10.1186/s12872-025-05278-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Semaglutide, a GLP-1 receptor agonist (GLP-1RA), has shown potential in controlling type 2 diabetes due to their ability to lower blood glucose and improve cardiovascular outcomes. Although semaglutide is the newest GLP-1RA available, its cardiovascular effects have not yet been systematically reviewed. METHODS: This meta-analysis adhered to a pre-registered protocol (PROSPERO ID: CRD42024538847). PubMed, Scopus, and Web of Science were searched comprehensively on February 26, 2024, to locate randomized controlled trials (RCTs) assessing semaglutide's impact on cardiovascular outcomes. A random effects model was used to analyze the data and the Cochrane risk of bias 2 tool was used to assess the quality of included studies. RESULTS: There were four RCTs involving 27,617 individuals (13,809 receiving semaglutide and 13,808 receiving placebo). There was a significant reduction in the risk of major adverse cardiovascular events (MACE) after administration of semaglutide (RR: 0.81, 95% CI: 0.74-0.88, p < 0.001, I 2 : 0.00%). Additionally, benefits were observed for particular findings such as cardiovascular death and nonfatal myocardial infarction."},{"id":"source_10","type":"source","study":"Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial","year":2026,"doi":"10.1038/s41591-026-04281-1","url":"https://doi.org/10.1038/s41591-026-04281-1","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In the SELECT trial, once-weekly subcutaneous semaglutide reduced major adverse cardiovascular events (MACE) by 20% versus placebo in patients with atherosclerotic cardiovascular disease and obesity but without diabetes. We examined semaglutide in SELECT patients at high risk for substantial liver fibrosis in a prespecified secondary analysis. Liver biochemical tests and steatosis risk according to fatty liver index were assessed over 104 weeks. Subgroup analyses of the primary MACE (a composite endpoint including cardiovascular death, nonfatal myocardial infarction or nonfatal stroke) outcome used baseline Fibrosis-4 scores ≥ 1.3, age-specific (≥1.3 (<65 years) or ≥2.0 (≥65 years)) and any age with Fibrosis-4 > 2.67. MACE was reduced by 26% (hazard ratio (HR) 0.74; 95% confidence interval (CI) 0.63-0.88; P = 0.0004), 21% (HR 0.79; 95% CI 0.63-0.98; P = 0.035) and 34% (HR 0.66; 95% CI 0.39-1.10; P = 0.11), respectively. Semaglutide led to a 28% greater decrease in fatty liver index versus placebo (HR 0.72; 95% CI 0.71-0.73; P < 0.0001)."},{"id":"source_11","type":"source","study":"Semaglutide promotes bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial","year":2025,"doi":"10.1093/eurheartj/ehaf690","url":"https://doi.org/10.1093/eurheartj/ehaf690","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"BACKGROUND AND AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce major atherosclerotic cardiovascular events in individuals living with either diabetes or obesity. Since the turnover of vascular regenerative (VR) stem and progenitor cells has been demonstrated to modulate vessel repair and atherothrombotic risk, this study aimed to determine the effect of the GLP-1RA semaglutide on the levels of circulating VR cells. METHODS: SEMA-VR CardioLink-15 was a randomized translational trial of usual care vs semaglutide for 6 months in 46 participants with either type 2 diabetes and/or obesity plus atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk factors. Vascular regenerative cells were enumerated using multi-parametric flow cytometry for high aldehyde dehydrogenase activity (ALDHhi) and lineage-specific cell surface marker expression. The primary endpoint was the 6-month change in VR cell content. RESULTS: Compared with usual care (n = 24), semaglutide (n = 22) led to a greater increase in the number of VR cells [high aldehyde dehydrogenase 1A1 activity and low side scatter (ALDHhiSSClow): +0.8% vs +34.8%; P = ."},{"id":"source_12","type":"source","study":"Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER )","year":2026,"doi":"10.1111/dom.70436","url":"https://doi.org/10.1111/dom.70436","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"AIMS: To assess the real-world effectiveness of semaglutide versus tirzepatide in reducing major adverse cardiovascular events (MACE) among patients with overweight/obesity and established atherosclerotic cardiovascular disease (ASCVD) without diabetes in an insured US population. MATERIALS AND METHODS: This retrospective, observational cohort study used Komodo Research Data and included patients ≥45 years of age with overweight/obesity and ≥1 claim for myocardial infarction (MI), ischemic stroke, or peripheral artery disease first treated with semaglutide or tirzepatide between 13/5/2022-31/1/2025. Propensity score matching was used to balance key baseline characteristics between cohorts. Primary outcomes included revised 3-point MACE (rMACE-3: MI, stroke, all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularization, hospitalisation for heart failure). Cox proportional hazard models were used to compare time to first event for study outcomes. A secondary per-protocol analysis was conducted where patients were censored at treatment discontinuation (gap in therapy >30 days). RESULTS: 10 625 patients were included in each matched cohort."},{"id":"source_13","type":"source","study":"Semaglutide reduces cardiovascular events in type 2 diabetes: a systematic review and meta-analysis highlighting enhanced benefits in chronic kidney disease","year":2025,"doi":"10.1186/s40001-025-03241-8","url":"https://doi.org/10.1186/s40001-025-03241-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Cardiovascular disease (CVD) disproportionately affects type 2 diabetes (T2D) patients with chronic kidney disease (CKD). Although semaglutide shows cardiometabolic benefits, its efficacy across CVD endpoints and high-risk CKD subgroups remains underexplored. METHODS: We systematically reviewed PubMed, Embase, Cochrane, Web of Science (through September 2025) for randomized trials and observational studies evaluating oral semaglutide versus placebo in T2D. Data synthesis employed hazard ratios (HRs) and mean differences (MDs) with 95% confidence intervals (CIs). RESULTS: Across 17 studies (n = 40, 632 patients), semaglutide significantly reduced the risk of cardiovascular (CV) death by 23% [HR 0.77, 95% CI (0.68, 0.88)], major adverse cardiovascular events (MACE) by 18% [HR 0.82, 95% CI (0.75, 0.90)], expanded MACE by 22% [HR 0.78, 95% CI (0.70, 0.85)], nonfatal myocardial infarction (MI) by 18% [HR 0.82, 95% CI (0.68, 0.92)], and nonfatal stroke by 32% [HR 0.68, 95% CI (0.56, 0.83)]. The reductions in CV events were most pronounced in T2D patients with CKD (24-37% risk reduction vs. 13-35% in T2D alone or with CVD)."},{"id":"source_14","type":"source","study":"Semaglutide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.","year":2026,"doi":"10.1016/j.eprac.2025.11.018","url":"https://doi.org/10.1016/j.eprac.2025.11.018","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"OBJECTIVES: To evaluate semaglutide's multisystem therapeutic benefits across 12 health domains. Primary outcomes were major adverse cardiovascular events, resolution of metabolic dysfunction-associated steatohepatitis, and composite renal endpoints. METHODS: PubMed, Embase, and Cochrane Central were searched through June 30, 2025, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. Eligible studies included randomized controlled trials in adults (≥18 years) with ≥24-week follow-up comparing semaglutide (≥0.5 mg weekly subcutaneous or ≥7 mg daily oral) versus placebo or active comparators. Two reviewers independently extracted data and assessed bias (RoB 2) and certainty (GRADE). RESULTS: Thirty-five trials (n = 36 847; mean age 54.2 years; body mass index: 34.8 kg/m 2 ) were included. Semaglutide reduced glycated hemoglobin (-1.52%, 95% confidence interval [CI]: -1.60 to -1.44) and weight (-12.4 kg, 95% CI: -13.0 to -11.8). Non-glycemic benefits included major adverse cardiovascular events reduction (16%, risk ratio [RR]: 0.84, 95% CI: 0.77-0.92), metabolic dysfunction-associated steatohepatitis resolution (62.9%, RR: 1.84, 95% CI: 1.49-2."},{"id":"source_15","type":"source","study":"Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials","year":2026,"doi":"10.3389/fmed.2026.1764664","url":"https://doi.org/10.3389/fmed.2026.1764664","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"BACKGROUND: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide, (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as an effective therapy for obesity and type 2 diabetes mellitus (T2DM). Its dual-incretin mechanism may offer enhanced metabolic benefits compared with selective GLP-1 receptor agonists such as semaglutide. METHODS: A structured narrative review of clinical trials, real-world observational studies, and contextual cardiovascular outcome analyses was conducted. Literature was sourced from ClinicalTrials.gov and relevant scientific databases to compare tirzepatide and semaglutide across weight, glycemic, cardiometabolic, and safety outcomes. RESULTS: Across completed head-to-head randomized trials, tirzepatide consistently achieved greater reductions in body weight, and HbA1c than semaglutide in individuals with obesity or T2DM. Semaglutide, however, has the most mature evidence for cardiovascular risk reduction, as demonstrated in the SUSTAIN-6, PIONEER-6, and SELECT trials."},{"id":"source_16","type":"source","study":"Abstract 4367243: Comparative Effects of Tirzepatide vs Semaglutide on 1-Year Mortality and Cardiovascular Outcomes in T2DM Patients with HFpEF","year":2025,"doi":"10.1161/circ.152.suppl_3.4367243","url":"https://doi.org/10.1161/circ.152.suppl_3.4367243","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"However, direct comparative data between Tirzepatide and Semaglutide in this high-risk population remain limited. </jats:p> <jats:p> <jats:bold>Hypothesis:</jats:bold> We hypothesized that among patients with T2DM and HFpEF, treatment with Tirzepatide would be associated with improved 1-year outcomes compared to semaglutide. </jats:p> <jats:p> <jats:bold>Methods:</jats:bold> Using the TriNetX network, we identified adults (≥18 years) with T2DM and HFpEF who were initiated on Tirzepatide or Semaglutide. Odds ratios (OR) with 95% confidence intervals (CI) and p-values were reported for each outcome. </jats:p> <jats:p> <jats:bold>Results:</jats:bold> After matching, baseline characteristics were well balanced between the Tirzepatide and Semaglutide groups."}],"edges":[{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_1","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_2","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_3","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_4","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_5","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_6","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_7","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_8","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_9","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_10","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_11","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_12","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_13","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_14","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_15","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_16","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_17","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_18","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_19","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_20","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_21","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_22","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_23","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_24","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_25","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_26","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_27","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_28","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_29","type":"contains_claim"},{"from":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","to":"claim_30","type":"contains_claim"}],"screening":{"identified":16,"screened":16,"excluded":0,"included":16,"included_or_retained":16,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"16 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}},{"name":"contradiction_map.json","media_type":"application/json","content":{"publication_id":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","screening":{"identified":16,"screened":16,"excluded":0,"included":16,"included_or_retained":16,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"16 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["Evidence-honesty note: 15/16 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated significant weight loss and glycemic benefits, prompting investigation into its potential cardiovascular protective effects across diverse patient populations. This synthesis employs an AI-assisted structured evidence approach, systematically integrating data from 16 curated reference papers, including systematic reviews, meta-analyses, and observational cohorts, to evaluate the cardiovascular impact of semaglutide. However, evidence regarding all-cause mortality remains mixed, with one meta-analysis reporting beneficial effects (Sillassen 2025) while a comparative analysis in patients with heart failure with preserved ejection fraction found no significant difference between semaglutide and tirzepatide (Abstract 2025). Significant tensions exist within the evidence base, notably regarding the consistency of effects on safety comorbidity outcomes between reviews (Sillassen 2025 vs. Mann 2025) and on contextual cardiovascular outcomes between positive observational data and mechanistic analyses (Smolderen 2025 vs. Tan 2025).","However, evidence regarding all-cause mortality remains mixed, with one meta-analysis reporting beneficial effects (Sillassen 2025) while a comparative analysis in patients with heart failure with preserved ejection fraction found no significant difference between semaglutide and tirzepatide (Abstract 2025).","The geroscience hypothesis proposes that targeting fundamental aging biology — rather than individual diseases in isolation — may yield multiplicative health benefits, a logic that has motivated the repurposing of existing pharmacotherapies alongside novel geroprotector development. Within this framework, agents that modulate inflammation, metabolic signaling, and cellular stress pathways are of particular interest, as these mechanisms appear to intersect with multiple age-related pathologies simultaneously. Semaglutide Cardiovascular Effects enters this discourse because glucagon-like peptide-1 receptor agonists engage several pathways implicated in vascular aging, including endothelial function, inflammatory cascades, and hepatic lipid metabolism. Whether such mechanistic plausibility translates into clinically meaningful cardiovascular protection, however, remains uncertain, particularly when the drug is tested in populations without established atherosclerotic cardiovascular disease. The gap between mechanistic promise and hard-outcome evidence is a recurring tension in the geroscience literature, and Semaglutide Cardiovascular Effects exemplifies this challenge.","Several critical questions about Semaglutide Cardiovascular Effects remain unresolved. First, the mechanism by which the drug reduces cardiovascular events has been proposed to involve weight loss, glycemic improvement, blood pressure reduction, and direct vascular effects, but disentangling these pathways is challenging, particularly since a meta-analysis of obesity pharmacotherapies reported improvements across lipid profile, blood pressure, and hemoglobin A1c simultaneously (McGowan 2025). Second, the tradeoff between cardiovascular benefit and adverse effects — including gastrointestinal intolerance and potential skeletal concerns — is incompletely characterized, with one meta-analysis reporting mixed safety signals (Sillassen 2025) and the SOUL trial showing null findings for certain kidney outcomes (Mann 2025). Third, dose-response relationships remain uncertain: the 2.4 mg dose used in SELECT appears to confer cardiovascular protection, but whether lower doses achieve comparable effects in lower-risk populations has not been established.","This synthesis addresses the cross-outcome tensions and structured evidence weighting that characterize the Semaglutide Cardiovascular Effects literature. Across the 16 curated reference papers, cross-study disagreements emerge, with disagreements of severity 4 between studies reporting positive, mixed, null, and unclear effect directions on cardiometabolic, safety, and contextual outcomes. The evidence base shows a context-dependent profile: positive signals appear in certain contextual and cardiometabolic outcomes, while null findings dominate in safety and comorbidity domains (Smolderen 2025, Tan 2025, Wilson 2026). Rather than treating the literature as uniformly supportive or dismissive, this synthesis separates clinical evidence — derived from randomized controlled trials and their meta-analyses — from mechanistic evidence, and weights each domain according to study design, population directness, and outcome class. The goal is to provide a transparent map of where Semaglutide Cardiovascular Effects shows convergent support, where the evidence remains mixed or sparse, and where the boundary conditions for clinical application remain to be established. Such structured evidence synthesis may help clinicians and policymakers navigate the rapidly evolving landscape of glucagon-like peptide-1 receptor agonist cardiovascular evidence.","The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.","The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.","| Contextual Adjacent Evidence | n=6; claims=451 | mixed signal in 3/6 sources | 1 direct; 3 indirect; 2 review | limited corpus depth in this outcome class |","Contextual Adjacent Evidence: n=6; claims=451; mixed signal in 3/6 sources | directness: 1 direct; 3 indirect; 2 review; main limitation: directionally heterogeneous.","The evidence base for semaglutide's cardiovascular effects is built upon a corpus of five systematic reviews and meta-analyses that synthesize data from numerous randomized controlled trials and observational studies (Wu 2025; Sadraei 2025; Yao 2025; Eisa 2026; McGowan 2025). These reviews collectively examine populations with type 2 diabetes and overweight or obesity, analyzing endpoints including major adverse cardiovascular events (MACE), atrial fibrillation (AF), cardiovascular death, and metabolic parameters. For instance, the analysis by Wu 2025 specifically focused on arrhythmic, major cardiovascular, and renal outcomes, while Yao 2025 highlighted enhanced benefits in subgroups with chronic kidney disease. The duration of follow-up in the constituent trials varied, but the meta-analytic approach allows for pooled effect estimates across heterogeneous study populations. This body of work provides the quantitative foundation for evaluating semaglutide's cardiometabolic profile.","Within the corpus, the primary tension concerns the certainty and interpretation of the overall evidence, as reflected in the effect direction classifications. While most reviews report beneficial effects, the effect direction for several, including Wu 2025, Yao 2025, Eisa 2026, and McGowan 2025, is classified as 'unclear', whereas Sadraei 2025 is classified as 'mixed' (cross-study disagreement map). This discrepancy may stem from differences in included study populations, specific endpoint definitions, or statistical heterogeneity (I²) within the meta-analyses. By contrast, other reviews may have emphasized different subsets of outcomes or populations where the evidence was less consistent. This highlights that while the direction of effect for major endpoints is predominantly positive, the strength and uniformity of the evidence across all cardiometabolic outcomes requires careful interpretation."]}},{"name":"evidence_table.csv","media_type":"text/csv","content":"study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness\r\nThe adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nA systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nLower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World),not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\n\"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\n\"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nImpact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nOral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nEffects of subcutaneous or oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nCardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nSemaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nSemaglutide promotes bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nSemaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER ),not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nSemaglutide reduces cardiovascular events in type 2 diabetes: a systematic review and meta-analysis highlighting enhanced benefits in chronic kidney disease,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nSemaglutide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\n\"Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nAbstract 4367243: Comparative Effects of Tirzepatide vs Semaglutide on 1-Year Mortality and Cardiovascular Outcomes in T2DM Patients with HFpEF,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\n"},{"name":"risk_of_bias.json","media_type":"application/json","content":{"publication_id":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","doi":"10.1038/s41591-025-03978-z","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","doi":"10.1111/dom.70080","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","doi":"10.1186/s40001-025-03124-y","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","doi":"10.1002/edm2.70136","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial","doi":"10.2337/dc25-1080","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes","doi":"10.1001/jamacardio.2026.0245","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Effects of subcutaneous or oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","doi":"10.3389/fcvm.2025.1731127","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials","doi":"10.1186/s12872-025-05278-3","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial","doi":"10.1038/s41591-026-04281-1","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Semaglutide promotes bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial","doi":"10.1093/eurheartj/ehaf690","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER )","doi":"10.1111/dom.70436","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Semaglutide reduces cardiovascular events in type 2 diabetes: a systematic review and meta-analysis highlighting enhanced benefits in chronic kidney disease","doi":"10.1186/s40001-025-03241-8","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Semaglutide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.","doi":"10.1016/j.eprac.2025.11.018","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials","doi":"10.3389/fmed.2026.1764664","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Abstract 4367243: Comparative Effects of Tirzepatide vs Semaglutide on 1-Year Mortality and Cardiovascular Outcomes in T2DM Patients with HFpEF","doi":"10.1161/circ.152.suppl_3.4367243","risk_of_bias":"not appraised in public sidecar","directness":"review-level"}]}}]}